Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15382587 | 1.00 | CA1 (0.38) | CA1CA2CA14CXCR2MAPT | |
| SCHEMBL21261493 | 1.00 | CA1 (0.38) | CA1CA2CA14CXCR2MAPT | |
| SCHEMBL29308571 | 0.86 | CA1 (0.40) | CA1CA2CA14MAPTHTT | |
| SCHEMBL29308554 | 0.86 | CA1 (0.40) | CA1CA2CA14MAPTHTT | |
| SCHEMBL10088095 | 0.86 | CA1 (0.40) | CA1CA2CA14MAPTHTT | |
| SCHEMBL15922161 | 0.86 | HSD17B10 (0.35) | CXCR2MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL2326461 | 0.86 | HSD17B10 (0.35) | CXCR2MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL31565133 | 0.84 | CA14 (0.32) | CA1CA2CA14CXCR2CA12 | |
| SCHEMBL31565136 | 0.84 | CA14 (0.32) | CA1CA2CA14CXCR2CA12 | |
| SCHEMBL20399144 | 0.83 | MAPT (0.32) | CA1CA2CA14MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338621-B2 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8338621-B2 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8338621-B2 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| EP-1806339-B1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB PHARMA SA (BE) | 2011-08-17 | — | — | EP | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | CYP2F1, CYP3A5, SULT1E1 | CA1 2079/4885CA2 1508/4885CA14 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.